Roivant Sciences Ltd.
ROIV
Rang in Aktien
#973
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Aktienkurs
$33.73
Zuletzt synchronisiert: 2026-07-31
Marktkapitalisierung
$24.37B
Veränderung (1 Tag)
-2.28%
Veränderung (1 Jahr)
87.82%
Land
GB
Handel Roivant Sciences Ltd. (ROIV)
Kategorie
Healthcare
Kursverlauf für Roivant Sciences Ltd. (ROIV)
Höchster Schlusskurs: $34.87 am 2026-07-01
Niedrigster Schlusskurs: $10.07 am 2020-12-01
Niedrigster Schlusskurs: $10.07 am 2020-12-01
Kursverlauf der Aktie von Roivant Sciences Ltd. von 2020 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 23.70% |
| 2025 | 80.37% |
| 2024 | 13.38% |
| 2023 | 50.58% |
| 2022 | -31.41% |
| 2021 | 1.51% |
| 2020 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.16 | -4.25% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
